Generic placeholder image

Letters in Drug Design & Discovery

Editor-in-Chief

ISSN (Print): 1570-1808
ISSN (Online): 1875-628X

Research Article

Synthesis of Spiro[cycloalkane-pyridazinones] with High Fsp3 Character

Author(s): Csilla Sepsey Für, Gergő Riszter, János Gerencsér, Áron Szigetvári, Miklós Dékány, László Hazai, György Keglevich and Hedvig Bölcskei*

Volume 17, Issue 6, 2020

Page: [731 - 744] Pages: 14

DOI: 10.2174/1570180816666190710130119

Abstract

Background: Nowadays, in course of the drug design and discovery much attention is paid to the physicochemical parameters of a drug candidate, in addition to their biological activity. Disadvantageous physicochemical parameters can hinder the success of a drug candidate.

Objective: Lovering et al. introduced the Fsp3 character as a measure of carbon bond saturation, which is related to the physicochemical paramethers of the drug. The pharmaceutical research focuses on the synthesis of compounds with high Fsp3 character.

Methods: To improve the physicochemical properties (clogP, solubility, more advantageous ADME profile, etc.) of drug-candidate molecules one possibility is the replacement of all-carbon aromatic systems with bioisoster heteroaromatic moieties, e.g. with one or two nitrogen atom containing systems, such as pyridines and pyridazines, etc. The other option is to increase the Fsp3 character of the drug candidates. Both of these aspects were considered in the design the new spiro[cycloalkanepyridazinones], the synthesis of which is described in the present study.

Results: Starting from 2-oxaspiro[4.5]decane-1,3-dione or 2-oxaspiro[4.4]nonane-1,3-dione, the corresponding ketocarboxylic acids were obtained by Friedel-Crafts reaction with anisole or veratrole. The ketocarboxylic acids were treated by hydrazine, methylhydrazine or phenylhydrazine to form the pyridazinone ring. N-Alkylation reaction of the pyridazinones resulted in the formation of further derivatives with high Fsp3 character.

Conclusion: A small compound library was obtained incorporating compounds with high Fsp3 characters, which predicts advantageous physico-chemical parameters (LogP, ClogP and TPSA) for potential applications in medicinal chemistry.

Keywords: Pyridazinone, spiro[cycloalkane-pyridazinone], Fsp3 character, Friedel-Crafts reaction, spiro, ketocarboxylic acid, hydrazine, phenylhydrazine.

Graphical Abstract
[1]
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev., 1997, 23, 3-25. Ibid: Adv Drug Delivery Rev 2001; 46(1-3): 3-26.
[PMID: 11259830]
[2]
Lipinski CA. Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol 2004; 1(4): 337-41.
[http://dx.doi.org/10.1016/j.ddtec.2004.11.007] [PMID: 24981612]
[3]
Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 2002; 45(12): 2615-23.
[http://dx.doi.org/10.1021/jm020017n] [PMID: 12036371]
[4]
Gleeson MP. Generation of a set of simple, interpretable ADMET rules of thumb. J Med Chem 2008; 51(4): 817-34.
[http://dx.doi.org/10.1021/jm701122q] [PMID: 18232648]
[5]
Martin YC. A bioavailability score. J Med Chem 2005; 48(9): 3164-70.
[http://dx.doi.org/10.1021/jm0492002] [PMID: 15857122]
[6]
Pajouhesh H, Lenz GR. Medicinal chemical properties of successful central nervous system drugs. NeuroRx 2005; 2(4): 541-53.
[http://dx.doi.org/10.1602/neurorx.2.4.541] [PMID: 16489364]
[7]
Lovering F, Bikker J, Humblet C. Escape from flatland: increasing saturation as an approach to improving clinical success. J Med Chem 2009; 52(21): 6752-6.
[http://dx.doi.org/10.1021/jm901241e] [PMID: 19827778]
[8]
Lovering F. Escape from Flatland 2: complexity and promiscuity. MedChemComm 2013; 4: 515-9.
[http://dx.doi.org/10.1039/c2md20347b]
[9]
Ritchie TJ, Macdonald SJF. The impact of aromatic ring count on compound developability--are too many aromatic rings a liability in drug design? Drug Discov Today 2009; 14(21-22): 1011-20.
[http://dx.doi.org/10.1016/j.drudis.2009.07.014] [PMID: 19729075]
[10]
Ritchie TJ, Macdonald SJF, Young RJ, Pickett SD. The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types. Drug Discov Today 2011; 16(3-4): 164-71.
[http://dx.doi.org/10.1016/j.drudis.2010.11.014] [PMID: 21129497]
[11]
Wermuth CG. Are pyridazines privileged structures? MedChemComm 2011; 2: 935-41.
[http://dx.doi.org/10.1039/C1MD00074H]
[12]
Asif M. The Pharmacological Importance of Some Diazine Containing Drug Molecules. Scientific Online Publications Transactions on Organic Chemistry 2014; 1(1): 1-17.
[13]
Akhtar W, Shaquiquzzaman M, Akhter M, Verma G, Khan MF, Alam MM. The therapeutic journey of pyridazinone. Eur J Med Chem 2016; 123: 256-81.
[http://dx.doi.org/10.1016/j.ejmech.2016.07.061] [PMID: 27484513]
[14]
Vigil-De Gracia P, Lasso M, Ruiz E, Vega-Malek JC, de Mena FT, López JC. Severe hypertension in pregnancy: hydralazine or labetalol. A randomized clinical trial. Eur J Obstet Gynecol Reprod Biol 2006; 128(1-2): 157-62.
[http://dx.doi.org/10.1016/j.ejogrb.2006.02.015] [PMID: 16621226]
[15]
Papp Z, Édes I, Fruhwald S, et al. Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol 2012; 159(2): 82-7.
[http://dx.doi.org/10.1016/j.ijcard.2011.07.022] [PMID: 21784540]
[16]
(a)Kan JP, Mouget-Goniot C, Worms P, Biziere K. Effect of the antidepressant minaprine on both forms of monoamine oxidase in the rat. Biochem Pharmacol 1986; 35(6): 973-8.
[http://dx.doi.org/10.1016/0006-2952(86)90085-7] [PMID: 3954800] ; bContreras JM, Rival YM, Chayer S, Bourguignon JJ, Wermuth CG. Aminopyridazines as acetylcholinesterase inhibitors. J Med Chem 1999; 42(4): 730-41.
[http://dx.doi.org/10.1021/jm981101z] [PMID: 10052979]
[17]
Aleeva GN, Molodavkin GM, Voronina TA. Comparison of antidepressant effects of azafan, tianeptine, and paroxetine. Bull Exp Biol Med 2009; 148(1): 54-6.
[http://dx.doi.org/10.1007/s10517-009-0638-4] [PMID: 19902096]
[18]
Goldberg AD, Nicklas J, Goldstein S. The Imazodan Research Group Effectiveness of imazodan for treatment of chronic congestive heart failure. Am J Cardiol 1991; 68(6): 631-6.
[http://dx.doi.org/10.1016/0002-9149(91)90356-P] [PMID: 1715125]
[19]
Avcı D, Bahçeli S, Tamer O, Atalay Y. Comparative study of DFT/B3LYP, B3PW91, and HSEH1PBE methods applied to molecular structures and spectroscopic and electronic properties of flufenpyr and amipizone. Can J Chem 2015; 93: 1147-56.
[http://dx.doi.org/10.1139/cjc-2015-0176]
[20]
Ukena D, Rentz K, Reiber C, Sybrecht GW. Effects of the mixed phosphodiesterase III/IV inhibitor, zardaverine, on airway function in patients with chronic airflow obstruction. Respir Med 1995; 89(6): 441-4.
[http://dx.doi.org/10.1016/0954-6111(95)90214-7] [PMID: 7644776]
[21]
Summerfield NJ, Boswood A, O’Grady MR, et al. Efficacy of pimobendan in the prevention of congestive heart failure or sudden death in Doberman Pinschers with preclinical dilated cardiomyopathy (the PROTECT Study). J Vet Intern Med 2012; 26(6): 1337-49.
[http://dx.doi.org/10.1111/j.1939-1676.2012.01026.x] [PMID: 23078651]
[22]
Inskeep PB, Reed AE, Ronfeld RA. Pharmacokinetics of zopolrestat, a carboxylic acid aldose reductase inhibitor, in normal and diabetic rats. Pharm Res 1991; 8(12): 1511-5.
[http://dx.doi.org/10.1023/A:1015894300247] [PMID: 1808615]
[23]
Dyck B, Markison S, Zhao L, et al. A thienopyridazinone-based melanin-concentrating hormone receptor 1 antagonist with potent in vivo anorectic properties. J Med Chem 2006; 49(13): 3753-6.
[http://dx.doi.org/10.1021/jm051263c] [PMID: 16789729]
[24]
Giovannoni MP, Vergelli C, Biancalani C, et al. Novel pyrazolopyrimidopyridazinones with potent and selective phosphodiesterase 5 (PDE5) inhibitory activity as potential agents for treatment of erectile dysfunction. J Med Chem 2006; 49(17): 5363-71.
[http://dx.doi.org/10.1021/jm060265+] [PMID: 16913726]
[25]
Badger AM, Schwartz DA, Picker DH, et al. Antiarthritic and suppressor cell inducing activity of azaspiranes: structure-function relationships of a novel class of immunomodulatory agents. J Med Chem 1990; 33(11): 2963-70.
[http://dx.doi.org/10.1021/jm00173a010] [PMID: 2146392]
[26]
Norris WSGP, Thorpe JF. The Formation and Stability of spiro-Cornpounds. Part V. Derivatives of cycloHexanespirocyclohexane and of cycloPentanespirocyclohexane. J Chem Soc 1921; 1199-210.
[http://dx.doi.org/10.1039/CT9211901199]
[27]
Stengel T, Maier T, Mann A, et al. 2012.
[28]
Coates WJ, McKillop A. One-Pot Preparation of 6-Substituted 3(2H)-Pyridazinones from Ketones. Synthesis 1993; 3: 334-42.
[http://dx.doi.org/10.1055/s-1993-25861]
[29]
Van der Mey M, Hatzelmann A, Van der Laan IJ, Sterk GJ, Thibaut U, Timmerman H. Novel selective PDE4 inhibitors. 1. Synthesis, structure-activity relationships, and molecular modeling of 4-(3,4-dimethoxyphenyl)-2H-phthalazin-1-ones and analogues. J Med Chem 2001; 44(16): 2511-22.
[http://dx.doi.org/10.1021/jm010837k] [PMID: 11472205]
[30]
Van der Mey M, Hatzelmann A, Van Klink GPM, et al. Novel selective PDE4 inhibitors. 2. Synthesis and structure-activity relationships of 4-aryl-substituted cis-tetra- and cis-hexahydrophthalazinones. J Med Chem 2001; 44(16): 2523-35.
[http://dx.doi.org/10.1021/jm010838c] [PMID: 11472206]
[31]
Vickery EH, Pahler FL, Eisenbraun EJ. Selective O-Demethylation of Catechol Ethers. Comparison of Boron Tribromide and Iodotrimethylsilane J Org Chem 1979; 44(24): 4444-6.
[http://dx.doi.org/10.1021/jo01338a043]

© 2022 Bentham Science Publishers | Privacy Policy